Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters ...

The AI Change That Let Pfizer’s Albert Bourla Sleep Better ...

Pfizer outlook improves beyond COVID as cost cuts target $2.7B by 2029, though patents and pricing pose risks.

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...

Use code Dividendology10 for 10% off Forecaster!: Join my newsletter! In this video, we analyze 2 stocks members of congress ...

The company is entering what could be a particularly challenging period.

Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 3 study called “AN INTERVENTIONAL PHASE 3 STUDY TO ...

Pfizer will cut around 330 jobs in Italy at its Sicily plant, ​labour unions said on Wednesday, making ‌the US drugmaker the ...

The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...